ClinicaliQ Trial Snapshot
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer — Active Not Recruiting • Phase III • Oncology • NCT03732820.
- Adding olaparib to abiraterone improves outcomes versus abiraterone alone in men with newly-diagnosed advanced prostate cancer.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage. Conditions: Metastatic Castration-resistant Prostate Cancer Interventions: olaparib, abiraterone acetate Lead Sponsor: AstraZeneca Planned Enrollment: 895 participants